ANBL1821 - A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma

This Study is
No Longer Enrolling

Details
Age

Child to Adult

Type of Study

Treatment

Locations

Childrens Hospital Colorado

Study ID

Protocol Number: 19-1259

More information available at ClinicalTrials.gov: NCT03794349

Categories

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers